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p53 was originally detected as a 53 kDa nuclear phosphoprotein co-immunoprecipitating with SV40 large T antigen (Lane & Crawford. 1979 : Linzer & Levine, 1979 . It has since been shown to have a sequence-specific DNA-binding capability which regulates entry into the S phase of the cell cycle at a transcriptional level (Kern et al.. 1991) . Both cytogenetic (Muleris et al.. 1985) and restriction fragment length polymorphism (RFLP) studies (Vogelstein et al.. 1989) have shown that loss of the p53 gene is a common event in human cancers. In addition to deletion of the gene, more recent studies have shown that mutation of the p53 coding sequence is also a common occurrence in a wide range of human tumours (Nigro et al.. 1989 : Hollstein et al.. 1991 . Alterations of the p53 gene are now known to be among the most frequent genetic changes occurring in human malignancies (Hollstein et al., 1991; Caron de Fromentel & Soussi. 1992) . Mutation or deletion of this gene effectively removes the regulatory influence of wild-type p53 protein on cell proliferation and may confer a growth advantage on a neoplastic population. This has led researchers to hypothesise that alterations in the p53 gene play a fundamental role in tumour development and progression.
Mutations occur most often in four of the five phylogenetically conserved regions of the p53 gene (Hollstein et al.. 1991; Caron de Fromentel & Soussi, 1992) . When mutations occur within these regions they generally result in an altered or 'mutant' p53 protein product. Although wildtype p53 protein, because of its short half-life, is normally present at very low levels in the cell, changes in conformation brought about by mutation apparently stabilise the mutant protein (Levine et al.. 1991) . The resultant accumulation of mutant protein may be detected by immunocytochemistry (ICC) . Overexpression of the p53 protein detected by ICC has now been used in a large number of studies on various tumour types as a marker of p53 gene mutation (Bartek et al., 1991; Porter et al., 1992) .
Although some studies have shown a good correlation between ICC staining and the presence of mutations within the p53 gene as detected by molecular analysis (Rodrigues et al., 1990; Davidoff et al., 1991; Marks et al.. 1991; Kohler et al.. 1992; Maestro et al., 1992; Somers et al., 1992; Thor et al.. 1992) . others have revealed varying degrees of discordancy (Barton et al.. 1991; Allred et al.. 1993; Kohler et al.. 1993 ). Indeed. the use of ICC as an indicator of p53 gene mutation has been questioned (Wynford-Thomas. 1992 
The standard reaction mixture (25gl) (Figure 1 ). Occasionally mutant bands were also detected between the single-and double-stranded bands and are probably caused by normal/mutant heterodimers. In all cases, normal p53 banding patterns were also observed. Since previous work by our group has shown that p53 allelic loss occurs in 75% of these tumours (Iacopetta et al., 1994) , these normal bands probably arise from either an admixture of normal tissue adjoining the tumour sample and/or tumour heterogeneity. All mutations were confirmed by reamplifying samples and running on separate SSCP gels. Whenever the tumour DNA revealed a p53 mutation, the corresponding germ-line DNA was also analysed by SSCP. No germ-line mutations were found, indicating that the changes were of somatic origin. Mutations were found in 37% (40/109) of carcinomas ( Table I ). The distribution of these mutations was 41%
(17/41) in exon 5, 12% (5/41) in exon 6, 15% (6/41) in exon 7 and 32% (13/41) in exon 8. In one tumour (84T) two mutations were found in exon 5 and another in exon 8. Several of the most commonly occurring mutant bands detected by SSCP were sequenced and found to contain mutations at codons 175 and 248 (Table II) , corresponding to two of the previously identified 'hotspot' regions (Nigro et al., 1989; Hollstein et al., 1991; Caron de Fromentel & Soussi, 1992) . None of the mutations we sequenced was found to be a conservative basepair change. Because the primers used in this study cross the intron-exon boundary, splice donor/acceptor mutations should have been detected by SSCP analysis. However, none of the mutations we sequenced was in this region (Table II) .
The sensitivity of the SSCP technique in identifying mutant DNA in the presence of large amounts of normal DNA is dependent on the resolution of the SSCP gel. Overexposure of the gel will eventually reveal all aberrantly migrating bands, providing they are sufficiently well separated from the normal bands. To determine the sensitivity of our SSCP gels, normal and mutant DNA bands from two different tumours were excised, eluted, ampliied and rerun to confirm the purity of these DNA templates. They were then diluted to the same concentration and the normal and mutant alleles mixed at varying ratios from 1.5% mutant DNA to 50% mutant DNA. These mixes were amplified and run on SSCP gels (Figure 2) . In cases in which the aberrantly migrating bands were well separated from the normal bands, as little as 1.5% mutant DNA in the original template mix could be detected (Figure 2a) . Even when the mutant bands migrated close to normal bands, they could be detected in mixes containing 6-12% mutant DNA template (Figure 2b) .
In preliminary experiments, we optimised the sensitivity of our SSCP gels by running PCR fragments from the same tumour samples under widely varying conditions of temperature, buffer concentration, glycerol/acrylamide concentration, (Hollstein et al., 1991 reported (Barton et al., 1991; Wynford-Thomas, 1992; Alfred et al., 1993; Kohler et a!., 1993 possibly reflecting exposure to different dietary or environmental carcinogens. As described in the results (Figure 2) , we believe that the high resolution of our SSCP analysis allowed the identification of tumours containin very low levels of mutant p53 allele. For this reason we conclude that approximately 40% of colorectal carcinomas have at least some cells carrying mutations within exons 5-8 of the p53 gene (Table   I) .
T'he frequency of p53 protein overexpression detected using ICC on the same series of colorectal carcinoma specimens used for SSCP analysis was 46% (50/109). This is very similar to the range of 42-49% reported in previous ICC studies (Purdie et al., 1991; Scott et al., 1991; Cunninghmet al., 1992 (Campani et al., 1993; Lassam et al., 1993) and CM-1 (Jiko et al., 1993) . A comparative study of six different anti-p53 antibodies has shown DO-7 to be the most sensitive and specific for ICC detection of p53 protein in colorectal cancers (Baas et al., 1994) . Although the frequencies of p53 gene mutation and protein overexpression we observed were quite similar (37% and 46% respectively), the concordancy of results from the two techniques (i.e. both positive or both negative) was only 69% (75/109). Recently, Allred et al. (1993) reported 62% concordance between SSCP and ICC detection of p53 mutation in breast cancer. As proposed by these authors and others who have observed discrepancies between p53 gene mutation and protein overexpression (Borresen et al., 1991; Wynford-Thomas, 1992; Oliner et al., 1993; Slingerland et al., 1993) , several explanations could account for these findings. Firstly, for the group of SSCP-negative/ICCpositive tumours, (20% of cases) some mutations may have occurred outside exons 5-8. We believe that this is unlikely to account for all cases, however, especially in view of the very low frequency (<5%) of mutations known to occur outside the highly conserved regions of the p53 gene (Hollstein et al., 1991; Caron de Fromentel & Soussi, 1992 Figure  2a ). When mutant and normal bands were less well separated a higher mutant DNA content of about 6-12% was required for detection (Figure 2b ).
In addition, the SSCP technique may not be 100% sensitive, and therefore some mutations may have escaped detection. Another explanation for SSCP-negative/ICC-positive cases is that p53 protein may accumulate in the absence of gene mutation by forming complexes with other molecules (Lane & Crawford, 1979; Sarnow et al., 1982; Momand et al., 1992 and hence accumulation in the cell. Secondly, the mutated gene may code for a stop codon and lead to production of a truncated form of the protein or a halt in protein production altogether. Thirdly, the antibody used for the ICC staining may not have detected all mutant protein epitopes. We sequenced five of these 12 cases (12T, 47T, 82T, 90T and 97T) and found that four had mutations leading to amino acid substitutions and the fifth was a frameshift mutation which introduced a stop codon downstream (Table II) .
Despite the 31% (34/109) discordancy, the overall correlation between SSCP and ICC detection of p53 mutations is still highly significant (P<0.001). Wider screening for mutations outside of the conserved gene regions and the use of other antibodies in ICC staining are likely to have uncovered other mutations which would have reduced this percentage. Nevertheless, our results suggest that ICC detection of p53 protein overexpression does not always indicate the existence of an underlying gene mutation and vice versa. This observation in colorectal cancer confirms other recent studies in large numbers of lung cancer cell lines (Bodner et al., 1992) and primary breast cancers (Allred et al., 1993) . As suggested previously (Bodner et al., 1992) , overexpression of p53 protein may depend upon the type of gene mutation.
An obvious question which arises from this work is the comparative biological significnce, if any, of p53 gene mutations and protein overexpression in neoplasia. It has been suggested that ICC detects functionally significant mutations (Wynford-Thomas, 1992) . Certainly, in breast cancer, overexpression of p53 appears to be a significant marker of poor prognosis (Isola et al., 1992; Thor et al., 1992; Allred et al., 1993; Silvestrini et al., 1993) . In colorectal cancer, however, the association between ICC positivity and patient survival is still controversial (Scott et al., 1991; O'Connell et al., 1992; Remvikos et al., 1992; Starzynska et al., 1992; Sun et al., 1992; Yamaguchi et al., 1992; Bell et al., 1993) . Much less work has been done correlating p53 gene mutation and outcome. Two studies in breast cancer indicate poorer prognosis in the presence of p53 gene mutation (Allred et al., 1993; Thorlacius et al., 1993) , but to our knowledge none has been published so far on colorectal carcinoma. Although the post-operative follow-up time of patients whose tumours were examined in the current study is still quite short (average 30 months), our preliminary results show no significant correlation between p53 gene mutation and survival (Dix et al., 1994) .
